Boston Scientific's Strategic Acquisition of Penumbra

January 15, 2026 - 22:28

In a significant move, Boston Scientific has announced its intention to acquire Penumbra in a deal valued at $14.5 billion. This transaction, which combines cash and stock, sets Penumbra's share price at $374. The acquisition is poised to enhance Boston Scientific's existing vascular and neurovascular portfolios, enabling the company to offer an expanded range of treatments for critical cardiovascular conditions.

With this acquisition, Boston Scientific aims to strengthen its capabilities in addressing serious health issues such as pulmonary embolism, stroke, and deep vein thrombosis. The integration of Penumbra's innovative technologies and products will not only broaden the company's therapeutic options but also reinforce its position as a leader in the medical device industry.

This strategic move underscores Boston Scientific's commitment to advancing patient care and improving outcomes in the vascular and neurovascular spaces, ultimately benefiting healthcare providers and patients alike.